Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as None applicable
INV-202 · 3 trials · 3 indications
Mean change from baseline in body weight at Week 16 for INV-202 versus placebo
Measure of UACR at W16 in comparison to baseline to evaluate the effect of INV-202 in participants with diabetic kidney disease (DKD)
Safety and Tolerability as assessed by Adverse Events
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | INV-202, 10 mg |
| High dose | EXPERIMENTAL | INV-202, 50 mg |
| Placebo | PLACEBO_COMPARATOR | Placebo Matching size and number of tablets |
| Middle Dose | EXPERIMENTAL | INV-202, 20 mg |
| INV 202 10 mg | EXPERIMENTAL | INV-202 10 mg Arm |
| INV-202 25 mg | EXPERIMENTAL | INV-202 25 mg Arm |
| INV-202 | EXPERIMENTAL | INV-202 25mg by mouth once daily |
| Name | Type | Description |
|---|---|---|
| INV-202 | DRUG | tablet, once daily, oral |
| Placebo | DRUG | tablet, once daily, oral |
Inclusion Criteria: 1\. Male and female participants from 18 to 75 years of age 2. Able and willing to provide informed consent and to comply with scheduled visits and study procedures 3. BMI ≥ 30 kg/m2 4. Presence of at least 3 of the 5 following criteria at screening: i. Increased waist circumfer...
INV-202 is an investigational small molecule being developed for diabetic kidney disease, obesity, and metabolic syndrome. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
INV-202 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is currently in Phase 2 clinical trials for diabetic kidney disease, obesity, and metabolic syndrome.
INV-202 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, including studies in metabolic syndrome, diabetic kidney disease, and obesity. The drug remains investigational and has not received regulatory approval.
INV-202 has been studied in three completed clinical trials. NCT05282446 was a Phase 1 study in metabolic syndrome with 37 participants. NCT05514548 was a Phase 2 trial in diabetic kidney disease with 265 participants. NCT05891834 was a Phase 2 study in obesity and metabolic syndrome with 243 participants.
INV-202 is a distinct investigational drug developed by Novo Nordisk. No alternative names have been reported for this compound in the available clinical trial information.